Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)

Trial Profile

Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs A001-MeiraGTx (Primary)
  • Indications Retinal dystrophies
  • Focus Adverse reactions
  • Sponsors MeiraGTx
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 1 Dec 2023 to 1 Apr 2023.
    • 16 Aug 2017 Planned primary completion date changed from 1 Nov 2023 to 1 Apr 2023.
    • 07 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top